Brind.
  1. Oncolytics Biotech and Johnson & Johnson operate within the larger oncology ecosystem, with J&J setting market standards through successful acquisitions.

Johnson & Johnson acquired AbioMed in 2022, and the FDA subsequently issued an early alert regarding device failure related to the acquisition.

4 reports, 4 independent Updated Aug 3
Gone quiet
Reports
4
Developments
3
Repetition
25%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

Johnson & Johnson acquired AbioMed in 2022, and the FDA subsequently issued an early alert regarding device failure related to the acquisition.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA classified a defect in AbioMed's heart pump kits distributed across the US.1 source
  2. JNJ operates the Abiomed heart pump business.1 source
  3. J&J acquisition of AbioMed and FDA early alert regarding device failure.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • medicaldaily.com
  • bostonglobe.com
  • yahoo.com
  • MedTech DiveJ&J removes some Abiomed heart pump controllers from market This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newslette